Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Invitae Corp NVTAQ

Healthcare
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies... see more

Recent & Breaking News (GREY:NVTAQ)

Invitae to Open New Facility in North Carolina to Support Continued Growth

PR Newswire April 20, 2021

Invitae to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

PR Newswire April 20, 2021

AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition

PR Newswire April 19, 2021

Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer

PR Newswire April 15, 2021

Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions

PR Newswire April 8, 2021

Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide

PR Newswire April 5, 2021

Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives

PR Newswire April 5, 2021

Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions

PR Newswire April 1, 2021

Invitae Releases Inaugural Environmental, Social and Governance (ESG) Report

PR Newswire March 11, 2021

Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference

PR Newswire March 4, 2021

Invitae adds Medneon's risk assessment tools to its education and clinical support offerings

PR Newswire February 24, 2021

Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians

PR Newswire February 23, 2021

Invitae to Present at The Cowen 41st Annual Healthcare Conference

PR Newswire February 22, 2021

Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020

PR Newswire February 17, 2021

Invitae to Present at the 10th Annual SVB Leerink Global Healthcare Conference

PR Newswire February 10, 2021

Invitae to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021

PR Newswire February 3, 2021

Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering

PR Newswire January 26, 2021

Invitae Announces Pricing of Public Offering of Common Stock

PR Newswire January 21, 2021

Invitae Announces Proposed Public Offering of Common Stock

PR Newswire January 20, 2021

Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)

PR Newswire January 14, 2021